ENZ Enzo Biochem Inc

Price (delayed)

$1.4

Market cap

$68.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.55

Enterprise value

$75.8M

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous ...

Highlights
Enzo Biochem's debt has decreased by 10% YoY and by 4.2% QoQ
Enzo Biochem's quick ratio has plunged by 52% YoY and by 27% from the previous quarter
Enzo Biochem's net income has decreased by 46% from the previous quarter

Key stats

What are the main financial stats of ENZ
Market
Shares outstanding
48.72M
Market cap
$68.21M
Enterprise value
$75.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.52
Price to sales (P/S)
0.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.77
Earnings
Revenue
$98.83M
EBIT
-$26.77M
EBITDA
-$23.86M
Free cash flow
-$22.33M
Per share
EPS
-$0.55
Free cash flow per share
-$0.46
Book value per share
$0.92
Revenue per share
$2.03
TBVPS
$1.6
Balance sheet
Total assets
$85.2M
Total liabilities
$40.21M
Debt
$19.72M
Equity
$44.99M
Working capital
$20.33M
Liquidity
Debt to equity
0.44
Current ratio
1.84
Quick ratio
0.98
Net debt/EBITDA
-0.32
Margins
EBITDA margin
-24.1%
Gross margin
34.7%
Net margin
-26.9%
Operating margin
-23.4%
Efficiency
Return on assets
-27%
Return on equity
-46.9%
Return on invested capital
-38.7%
Return on capital employed
-43.9%
Return on sales
-27.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZ stock price

How has the Enzo Biochem stock price performed over time
Intraday
-0.71%
1 week
-9.68%
1 month
-2.1%
1 year
-56.11%
YTD
-2.1%
QTD
-2.1%

Financial performance

How have Enzo Biochem's revenue and profit performed over time
Revenue
$98.83M
Gross profit
$34.33M
Operating income
-$23.09M
Net income
-$26.58M
Gross margin
34.7%
Net margin
-26.9%
The operating margin has plunged by 67% from the previous quarter
Enzo Biochem's net margin has shrunk by 57% QoQ
The operating income has plunged by 54% from the previous quarter
Enzo Biochem's net income has decreased by 46% from the previous quarter

Growth

What is Enzo Biochem's growth rate over time

Valuation

What is Enzo Biochem stock price valuation
P/E
N/A
P/B
1.52
P/S
0.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.77
The EPS has contracted by 45% from the previous quarter
ENZ's equity is down by 33% YoY and by 17% from the previous quarter
The P/B is 33% less than the 5-year quarterly average of 2.3 and 30% less than the last 4 quarters average of 2.2
The P/S is 59% below the 5-year quarterly average of 1.7 and 36% below the last 4 quarters average of 1.1
The company's revenue fell by 15% YoY and by 8% QoQ

Efficiency

How efficient is Enzo Biochem business performance
The ROIC has plunged by 62% from the previous quarter
ENZ's ROE has shrunk by 60% QoQ
The ROS has plunged by 58% from the previous quarter
ENZ's ROA has dropped by 54% since the previous quarter

Dividends

What is ENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENZ.

Financial health

How did Enzo Biochem financials performed over time
ENZ's total assets is 112% greater than its total liabilities
Enzo Biochem's quick ratio has plunged by 52% YoY and by 27% from the previous quarter
The current ratio has contracted by 35% YoY and by 17% from the previous quarter
Enzo Biochem's debt is 56% lower than its equity
ENZ's equity is down by 33% YoY and by 17% from the previous quarter
The debt to equity has grown by 33% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.